Recent Updates
Recently added Catalysts
ARDX Positive Sentiment Score: 70/100

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

Tuesday, November 21, 2023 2 min read
Key Takeaway: Ardelyx, Inc. will participate in the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023. The session will include a fireside chat, accessible via a live webcast on the company's Investor Relations website. Ardelyx, which aims to address significant medical needs, has two approved products in the U.S. and is advancing its pipeline, including international collaborations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ardelyx is participating in a reputable healthcare conference.
  • The company has two commercial products approved in the U.S.
  • Ardelyx is pioneering innovative, first-in-class medicines.

Full Press Release Details

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Ardelyx management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 2:30 p.m. E.T. in New York City.
To access the live webcast of Ardelyx's session, please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 30 days following the event.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor), as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin has received approval for PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:

Frequently Asked Questions

When will Ardelyx participate in the Piper Sandler Conference?

Ardelyx will participate on November 29, 2023, at 2:30 p.m. E.T.

How can I access Ardelyx's live webcast?

Visit the Events & Presentations page in the Investor section of the Ardelyx website.

What are Ardelyx's approved products in the U.S.?

The approved products are IBSRELA® (tenapanor) and XPHOZAH® (tenapanor).

Who is developing tenapanor outside the U.S.?

Kyowa Kirin develops tenapanor in Japan, and Fosun Pharma in China.

How long will the webcast replay be available?

The replay will be available for 30 days after the event.

Tags: ARDX Viatris Investor Conferences Healthcare Ardelyx Piper Sandler healthcare conference tenapanor IBSRELA
Last updated: Nov 21, 2023